This report compiles published, predictive intelligence based on interviews with key opinion leaders (KOLs) on market-moving events that are expected to occur in Q3 2026.
The latest report, “Catalyst Monitor Q3 2026”, delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, Phase III trial results, PDUFA dates, and regulatory filings. The report covers 11 significant catalyst events that are expected to occur in Q3 2026.
Some of the catalysts covered in the report, include approval decisions for Takeda's oveporexton in Narcolepsy Type 1.
Additionally, experts also discuss expectations about the ongoing clinical trials such as Exelixis' Phase III trial in non-clear cell renal cell carcinoma (nccRCC), and more.
The Catalyst Monitor report is published on a quarterly basis. The data presented in this report reflects the database as of 19 June.
The latest report, “Catalyst Monitor Q3 2026”, delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, Phase III trial results, PDUFA dates, and regulatory filings. The report covers 11 significant catalyst events that are expected to occur in Q3 2026.
Some of the catalysts covered in the report, include approval decisions for Takeda's oveporexton in Narcolepsy Type 1.
Additionally, experts also discuss expectations about the ongoing clinical trials such as Exelixis' Phase III trial in non-clear cell renal cell carcinoma (nccRCC), and more.
The Catalyst Monitor report is published on a quarterly basis. The data presented in this report reflects the database as of 19 June.
Scope
- The Q3 Catalyst Monitor report offers exclusive forward-looking insights on Phase III results, regulatory drug approvals and more, based on exhaustive research and exclusive KOL interviews.
Reasons to Buy
- This report will enable the user to answer the following questions:
- - Which biopharma companies are expecting major milestones such as FDA decisions or late-stage trial completions and results in Q3 2026?
- - Which upcoming regulatory catalysts that are expected in Q3 2026 are likely to be market-moving events?
- - How do the number of expected regulatory events like trial initiations and trial completions in Q3 2026 compare to the previous quarter?
- - Which are the top therapy areas for market-moving catalysts in Q3 2026 compared to the previous quarter?
- - Which companies have the highest numbers of upcoming catalysts expected in Q3 2026?
- - How do KOLs assess the US approval prospects of Takeda's oveporexton in Narcolepsy Type 1?
- - What are the expectations regarding Definium Therapeutics's Phase III trial results for DTI20 in Generalized Anxiety Disorder?
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Exelixis
- Bold Therapeutics
- Merck
- Kyverna Therapeutics
- IGC Pharma
- Takeda Pharmaceutical
- BPGbio
- ScandiBio Therapeutics
- Wave Life Sciences
- Definium Therapeutics
- Ernexa Therapeutics
